Michael Halstead Insider Profile
4 Followers
Michael Halstead, Chief Executive Officer at Helus Pharma, holds 168.57K shares in Helus Pharma (Ticker: HELP), holds 0.00 shares in Intra-Cellular Therapies (Ticker: ITCI), holds 15.36K shares in Warner Chilcott (Ticker: WCRX). Most recently, Michael Halstead Bought ― shares of Helus Pharma on Sep 21, 2026 for an estimated value of $1.35M.
Michael Halstead Helus Pharma (HELP)Chief Executive Officer
Helus Pharma (HELP)
Chief Executive Officer
Ranked #18,543 out of 109,193 Corporate Insiders
Profitable Transactions
1 out of 3 Profitable Transactions
Average Return
+55.70%
Average return per transaction
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of Michael Halstead's holdings
Insider Roles
Chief Executive Officer
Roles that Michael Halstead holds in companies
Most Profitable Insider Trade
Stock:
Intra-Cellular Therapies
(ITCI)
(ITCI)
Rating:Informative Buy
Date:Nov 06, 2014 - Nov 06, 2015
Return:+229.90%
The most profitable trade made by Michael Halstead
Michael Halstead's Trading History
Helus Pharma
Sep 21, 2026
Chief Executive Officer
Informative Buy
1.35M
$2.01M
Intra-Cellular Therapies
Apr 02, 2025
―
Uninformative Sell
2.81M
$0.00
Warner Chilcott
Jun 02, 2011
―
Uninformative Buy
―
―
List of latest transactions for each holding click on a transaction to see Michael Halstead's performance on stock
You May Also Like
Michael Halstead insider profile FAQ
What is the percentage of profitable transactions made by Michael Halstead?
The percentage of profitable transactions made by Michael Halstead is 33%.
What is the average return per transaction made by Michael Halstead?
The average return per transaction made by Michael Halstead is 55.70%.
What stocks does Michael Halstead hold?
Michael Halstead holds: HELP, ITCI, WCRX stocks.
What was Michael Halstead’s latest transaction?
Michael Halstead latest transaction was an Informative Buy of $1.35M.
What was Michael Halstead's most profitable transaction?
Michael Halstead’s most profitable transaction was an Informative Buy of ITCI stock on November 6, 2014. The return on the trade was 229.90%.
What is Michael Halstead's role in Helus Pharma?
Michael Halstead's role in Helus Pharma is Chief Executive Officer.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.